Company intelligence / Profile preview

Glytec

Waltham, Massachusetts, United States

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Glytec's Glucommander platform is FDA-cleared and has been validated in over 100 peer-reviewed publications to reduce severe hypoglycemia by up to 99.8%, lower 30-day readmissions by 36–68%, and reduce average hospital length of stay by up to 3.2 days. Trusted by more than 400 hospitals, with demonstrated ROI and outcome improvements in large-scale, real-world deployments.

Therapeutic areas: Endocrinology
Modalities: DeviceSoftware
Industry: Digital Health Medical Devices

Partnerships

Roche Diagnostics

Beyond the preview

Go deeper on Glytec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glytec.

Explore the full profile